Significant milestone re Thermo Fisher agreement

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, notes that Thermo Fisher Scientific has confirmed the completion of the transfer and achievement of all transfer-related activities for the pre-transplant prognostic testing technology licensed by the Company to Thermo Fisher Scientific under the terms of a global licensing and commercialisation agreement announced on 15 November 2023 (the "Agreement")1.

This enables Thermo Fisher Scientific to use the technology to develop a LDT ("Laboratory Developed Test") in its own labs. This event triggers a further milestone payment under the Agreement, in line with previously disclosed expectations.

Commenting on the milestone, Sara Barrington, CEO of Verici Dx, said:

"I am delighted to announce this smooth transition between Verici Dx and Thermo Fisher Scientific. This collaboration brings together Verici Dx's innovative technology into Thermo Fisher's new CLIA laboratory in the U.S., which will ultimately benefit patients and the field of organ transplantation."

• Please refer to RNS number 4652T for further information. A copy of this announcement can also be found on the company website https://verici-dx-plc.flint-platform.com/regulatory-news/62760